High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.

Ralph Tayyar, Lisa Kanata Wong,Alex Dahlen,Elaine Shu,Suchitra Pandey,Anne Y Liu

Transplant infectious disease : an official journal of the Transplantation Society（2023）

引用 1|浏览31

暂无评分

摘要

CCP is a safe, globally available treatment for immunocompromised patients with COVID-19. Mortality was lower in our cohort than that of COVID-19 patients with similar immunocompromising conditions. Post-vaccine CCP with very high titers should be prioritized for study in immunocompromised patients. Post-vaccine CCP has the potential to keep pace with new variants by overcoming mutations at sufficiently high titer.

查看译文

关键词

COVID-19 convalescent plasma,SARS-CoV-2,hematopoietic cell transplant,immunocompromised patients,solid organ transplant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要